In the present study we assessed the effects of naltrexone, an opioid antagonist (50mg) on the subjective physiological and biochemical response to dexamphetamine (30mg) in 20 In clinical studies, Jayaram-Lindstrom et al found that naltrexone reduced amphetamine-reinforcing effects in healthy volunteers ; was well tolerated by amphetamine dependent
Amphetamine Dependence Nitya Jayaram-Lindström Stockholm 2007
, Beck O
Consistent with laboratory findings, both naltrexone and bupropion have demonstrated superiority to placebo for reducing amphetamine use in some patients
Among adults with methamphetamine use disorder, the response over a period of 12 weeks among participants who received extended-release injectable naltrexone plus oral
Introduction
S
The unselective opioid receptor antagonist naltrexone (NTX) modulates amphetamine‐induced effects in both laboratory animals and humans
5 DOI: 10
023 Corpus ID: 51958689; Cue reactivity and opioid blockade in amphetamine dependence: A randomized, controlled fMRI study
In animal studies the opioid antagonist naltrexone has been shown to attenuate the subjective effects of amphetamine
trial of naltrexone for amphetamine dependence: Compliance and tolerabilty
This medication is a mu-opioid receptor antagonist and also a weaker antagonist of the kappa and delta-opioid
Nordic Journal of Psychiatry
Advanced Search Coronavirus articles and preprints Search examples: "breast cancer" Smith J Introduction
Hurd While dopaminergic mechanisms in amphetamine-taking behavior have been extensively studied, the contribution of the endogenous opioid system is less clear
This was measured using a Visual Analog Scale, assessing the subjective effects over 7 hours
Amphetamine abuse and dependence, which commonly involve reoccurrences and relapses, constitute a major public health problem
Addict Biol
Amphetamine* Amphetamine-Related Disorders / drug therapy* Humans Methamphetamine* Naltrexone / therapeutic use* Naltrexone’s seemingly broad anti-addiction efficacy supports a shared role for brain opioid pathways in the pathophysiology of addiction, broadly defined